By Jennifer Tsang
Read More
Over the past several months, we’ve seen the emergence of several SARS-CoV-2 variants coincide with increased vaccination efforts. So, how effective are the current vaccines against the variants?
This post was contributed by Ignacio Amigo and María Hernández Sánchez from Crowdfight. In March 2020, while most of the world was locked down, a South African company wanted to test if a type of antibodies from an Andean mammal called alpaca could neutralize the SARS-CoV-2 ...
These are stormy times. It feels like we’re being buffeted by wind and waves and sometimes wonder if we can take another blow. Back in March, we never expected to be in this here and now. Our closure was earlier than most companies. Since the start of this crisis, we’ve been ...
Scientists need fast access to the tools required to study SARS-CoV-2, but with many academic research labs closed during the pandemic, it’s hard to get these reagents. However, when reagents have been made available through a repository, they remain accessible during these ...
This post was contributed by Max W. Shen from MIT, Alvin Hsu Harvard University, and David R. Liu from the Broad Institute and Harvard University. Over the course of the last six months, COVID-19 has had a tremendous impact on our world -- as of June 4, 2020, COVID-19 has caused ...
By Susanna Bachle and Matt Takvorian When COVID-19 researchers started working with us to help them share their reagents, we knew our role in fighting the pandemic could be even more impactful by reaching more scientists. Many members of the scientific community support open ...
Nanobodies from camelids have gotten a lot of press for being a promising approach for treatment or prophylaxis of COVID-19. Researchers identified nanobodies that bind to coronavirus spike proteins (Wrapp et al., 2020), which sit on the surface of coronaviruses and enable the ...
